SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce the formation of a Clinical Advisory Committee to provide strategic advice and guidance on ZYUS’ clinical trial programs. Five committee members have been appointed to the Clinical Advisory Committee, adding additional medical, scientific, and clinical expertise to its experienced leadership team. This announcement is an important step in ZYUS’ integrated clinical development program and supports the company’s ambitions to pioneer the next generation of life sciences through an evidence-based approach.
Chaired by ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, a leading expert in chronic pain management and addictions medicine, the ZYUS Clinical Advisory Committee includes four initial committee members including Dr. Mary Lynch, Dr. David J. Shulkin, Dr. Cedric Francois and Dr. Alice Zwerling. As ZYUS scales its clinical trial programs, the Clinical Advisory Committee will work closely with the research team to provide input and guidance on clinical development strategies and evaluate the clinical trial progress.
Each of the named Clinical Advisory Committee members bring remarkable medical leadership and expertise to their advisory roles. Dr. Mary Lynch ranks among North America’s leading experts in pain management. She is a Professor in the Departments of Anesthesiology, Pain Management and Perioperative Medicine, Psychiatry and Pharmacology in the Faculty of Medicine at Dalhousie University. In addition to being the founding director of the Canadian Consortium for the Investigation of Cannabinoids, Dr. Lynch co-chairs the Canadian Pain Strategy and is a member of the Royal College of Physicians and Surgeons Working Group on Pain Management. Her expertise in pain management is directly aligned with ZYUS’ research into the potential of phyto-therapeutics to manage chronic and neuropathic pain, and Dr. Lynch’s scientific research and thought-leadership in this space will provide valuable guidance to ZYUS’ clinical approach.
Providing cross-border expertise and widely respected medical leadership, Dr. David J. Shulkin will bring his decades of experience leading some of North America’s largest and most sophisticated medical networks to the ZYUS Clinical Advisory Committee. Dr. Shulkin previously served as the ninth Secretary of the US Department of Veterans Affairs and prior to holding that role, was appointed Under Secretary for Health by President Obama and confirmed unanimously by the U.S. Senate. In his role as Secretary of the U.S. Department of Veterans Affairs, he represented 21 million American veterans and was responsible for the country’s largest integrated health care system with over 1,200 sites of care. In addition to his roles in the public sector, Dr. Shulkin has served as the chief executive of multiple hospitals and health systems, and has been named as one of the “One Hundred Most Influential People in American Healthcare” by Modern Healthcare. Dr. Shulkin’s experience as a physician, hospital CEO and Secretary of the Department of Veterans Affairs provides unique insights into the medical, societal and political implications of ZYUS’ clinical trial programs.
The co-founder and Chief Executive Officer and President of Apellis Pharmaceuticals, Dr. Cedric Francois is a global leader in medical and pharmaceutical innovation. Dr. Francois brings regulatory knowledge and clinical development expertise to ZYUS’ Clinical Advisory Committee and will play a key role in evaluating the clinical trial programs. Prior to his leadership role at Apellis, Dr. Francois served as President and Chief Executive Officer of Potentia Pharmaceuticals, a private biotechnology company he co-founded in 2001. He has implemented multiple successful clinical trials, developing and scaling new pathways in medicine to improve patient quality of life. Dr. Francois is recognized globally for his expertise in transplant surgery and in 2005, he was part of the team that completed the world’s first successful hand transplant. Since then he has continued to innovate protein-based therapeutics in categories ranging from hematology to COVID-19.
Dr. Zwerling is an Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa. She is an experienced epidemiologist with a focus on health economics. Dr. Zwerling received her PhD in Epidemiology from McGill University, and subsequently specialized in health economic evaluation during a postdoctoral fellowship at the Johns Hopkins Bloomberg School of Public Health. For more than a decade Dr. Zwerling has worked with partners in India, Southeast Asia and Africa, to end tuberculosis in the developing world. As ZYUS develops its drug program, Dr. Alice Zwerling will provide ZYUS with significant capability and insight into clinical trial design and data analysis.
“The caliber of our Clinical Advisory Committee members is a testament to the rigor, integrity and innovation of ZYUS’ research and clinical trial programs,” said ZYUS President & CEO Brent Zettl. “We are proud to welcome all four Clinical Advisory Committee Members, and look forward to their guidance, input and collaboration as ZYUS accelerates its mission to advance the science of well-being here in Canada, and around the world.”
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, expectations with respect to our business plans, research activities and product lines. Research and clinical trial programs are of an experimental nature and no particular results can be guaranteed.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information respecting the proposed research or results therefrom, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.